Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mario Zucca, Sara Scutera & Dianella Savoia. (2013) Novel avenues for Clostridium difficile infection drug discovery. Expert Opinion on Drug Discovery 8:4, pages 459-477.
Read now
Read now
A. I. Bamber, K. Fitzsimmons, J. G. Cunniffe, C. C. Beasor, C. A. Mackintosh & G. Hobbs. (2012) Diagnosis of Clostridium difficile-associated disease: examination of multiple algorithms using toxin EIA, glutamate dehydrogenase EIA and loop-mediated isothermal amplification. British Journal of Biomedical Science 69:3, pages 112-118.
Read now
Read now
Articles from other publishers (12)
Muni Kumar Mahadari, Sreenu Jennepalli, Andrew J. Tague, Papanin Putsathit, Melanie L. Hutton, Katherine A. Hammer, Daniel R. Knight, Thomas V. Riley, Dena Lyras, Paul A. Keller & Stephen G. Pyne. (2021) Cationic Peptidomimetic Amphiphiles Having a N-Aryl- or N-Naphthyl-1,2,3-Triazole Core Structure Targeting Clostridioides (Clostridium) difficile: Synthesis, Antibacterial Evaluation, and an In Vivo C. difficile Infection Model. Antibiotics 10:8, pages 913.
Crossref
Crossref
Andrew J. Tague, Papanin Putsathit, Melanie L. Hutton, Katherine A. Hammer, Steven M. Wales, Daniel R. Knight, Thomas V. Riley, Dena Lyras, Paul A. Keller & Stephen G. Pyne. (2019) Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an in vivo C. difficile infection model. European Journal of Medicinal Chemistry 170, pages 203-224.
Crossref
Crossref
Michael J. Aldape, Aaron E. PackhamDustin D. HeeneySavannah N. Rice, Amy E. Bryant & Dennis L. Stevens. (2017) Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficile
in vitro. Journal of Medical Microbiology 66:10, pages 1393-1399.
Crossref
Crossref
Shi-Hui Dong, Weixin Tang, Tiit Lukk, Yi Yu, Satish K Nair & Wilfred A van der Donk. (2015) The enterococcal cytolysin synthetase has an unanticipated lipid kinase fold. eLife 4.
Crossref
Crossref
Lynn Miesel, David W. Hecht, James R. Osmolski, Dale Gerding, Amy Flattery, Fangbiao Li, Jing Lan, Philip Lipari, Jon D. Polishook, Lianzhu Liang, Jenny Liu, David B. Olsen & Sheo B. Singh. (2014) Kibdelomycin Is a Potent and Selective Agent against Toxigenic Clostridium difficile. Antimicrobial Agents and Chemotherapy 58:4, pages 2387-2392.
Crossref
Crossref
Cristina de Souza Mendes & Adelaide de Souza Antunes. (2013) Pipeline of Known Chemical Classes of Antibiotics. Antibiotics 2:4, pages 500-534.
Crossref
Crossref
Carmela T. M. Mascio, Lawrence I. Mortin, Karen T. Howland, Andrew D. G. Van Praagh, Shuxin Zhang, Anu Arya, Cun Lan Chuong, Chunfeng Kang, Tongchuan Li & Jared A. Silverman. (2012)
In Vitro
and
In Vivo
Characterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficile
. Antimicrobial Agents and Chemotherapy 56:10, pages 5023-5030.
Crossref
Crossref
Vicki R. Kee. (2012) Clostridium Difficile Infection in Older Adults: A Review and Update on Its Management. The American Journal of Geriatric Pharmacotherapy 10:1, pages 14-24.
Crossref
Crossref
Jason W. Lancaster & S. James Matthews. (2012) Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections. Clinical Therapeutics 34:1, pages 1-13.
Crossref
Crossref
Daniela Jabes. (2011) The antibiotic R&D pipeline: an update. Current Opinion in Microbiology 14:5, pages 564-569.
Crossref
Crossref
Mark S Butler & Matthew A Cooper. (2011) Antibiotics in the clinical pipeline in 2011. The Journal of Antibiotics 64:6, pages 413-425.
Crossref
Crossref
Caoilfhionn OʼDonoghue & Lorraine Kyne. (2011) Update on Clostridium difficile infection. Current Opinion in Gastroenterology 27:1, pages 38-47.
Crossref
Crossref